In past work, we have shown neonatal quinpirole (dopamine D2/D3 agonist) treatment produces a significant increase in dopamine D2 receptor sensitivity, a phenomenon known as D2 receptor priming. Dopamine D2 receptor priming is common in psychosis. Male and female rats were administered quinpirole (1mg/kg) or saline from postnatal days 1-11 and raised to adulthood (P60). As adults, rats were administered d-amphetamine sulfate (1mg/kg) or saline every other day for 14 days. Approximately 10 min before each amphetamine or saline injection, animals were administered the D1 antagonist SCH 23390 (0.1 mg/kg), the D2 antagonist eticlopride (0.1 mg/kg) or saline. After both injections, rats were placed in a locomotor arena and activity was analyzed for a 10-min period. Results indicated that D2-priming enhanced locomotor activation effects to amphetamine in both males and females, with females demonstrating higher levels of behavioral activation. SCH 23390 blocked amphetamine sensitization in both males and females to levels below saline controls, whereas eticlopride was more effective in blocking amphetamine sensitization in males as compared to females, although eticlopride did block elevations of behavioral activation in D2-primed males and females. Seven to 10 days after sensitization, microdialysis was performed and amphetamine produced a five-fold increase in dopamine overflow in the nucleus accumbens compared to non D2-primed rats administered amphetamine. Both D1 and D2 antagonism were effective at blocking amphetamine-induced increases in dopamine overflow. These results show that neonatal quinpirole treatment enhances behavioral activation and dopamine overflow, but there appear to be sex differences in the D2 as compared to D1 response to behavioral activation produced by amphetamine.

Amphetamine abuse is an enduring problem in many developed nations, including Sweden. It causes lasting damage both to its users and in the form of increased strain on healthcare services. It is therefore critical that police be equipped with the tools necessary to rapidly and accurately identify any samples in order to combat this scourge. Current analysis methods rely on large complex machines such as gas-chromatographs. This causes a significant bottleneck as all samples must be sent to lab for analysis. In this report the potential application of graphene quantum dots(GQDs) as a sensor for amphetamine has been studied. These offer a potentially quick and cheap analysis method that could be integrated into an easily portable detector. It was found that GQDs synthesised by a simple method from citric acid shows increased photo-luminescence in the presence of amphetamine. The response is largely linear with increasing concentrations of amphetamine within an interval of 1mM-200mM. This indicates they may very well serve as a sensing element of an amphetamine detector. / Amfetaminmissbruk har länge varit ett problem i många industrialiserade länder, inklusive Sverige. Det skapar långvariga skador både på dess användare och i form av ökade kostnader för hälsovården. Det är därför kritiskt att polisen ges de verktyg som behövs för att snabbt och precist kunna analysera prov. Nuvarande analysmetoder använder sig av stora avancerade maskiner so som gas-kromatografer. Detta skapar en flaskhals då alla prov som tas måste skickas till labb för analys. I denna rapport har användningen av grafen kvantprickar (GQD) som en sensor för amfetamin studerats. Dessa har potentialen att ge en snabb och enkel analysmetod som skulle kunna integreras i portabel sensor. GQD:er syntetiserade med en simpel metod från citronsyra visas i dessa experiment ha ökad fotoluminiscens när de är lösta tillsammans med amfetamin. Denna respons är linjär relativt till koncentrationen av amfetamin inom intervallet 1mM-200mM. Detta indikerar att dessa GQD:er mycket väl kan användas som ett sensorelement i en amfetamindetektor.

No description available.

No description available.

No / Rationale Phencyclidine (PCP), a glutamate/N-methyl-d-aspartate (NMDA) receptor antagonist, has been shown to induce a range of symptoms similar to those of patients with schizophrenia, while d-amphetamine induces predominantly positive symptoms. Previous studies in our laboratory have shown that PCP can selectively impair the performance of an operant reversal-learning task in the rat. Furthermore, we found that the novel antipsychotic ziprasidone, but not the classical antipsychotic haloperidol, could prevent the PCP-induced deficit. Objectives The aim of the present study was to validate the model further using the atypical antipsychotic clozapine and then to investigate the effects of lamotrigine, a broad-spectrum anticonvulsant that is known to reduce glutamate release in vitro and is able to prevent ketamine-induced psychotic symptoms in healthy human volunteers. A further aim was to compare effects of PCP and d-amphetamine in the test and investigate the effects of the typical antipsychotic haloperidol against the latter. Methods Female hooded-Lister rats were food deprived and trained to respond for food in a reversal-learning paradigm. Results PCP at 1.5 mg/kg and 2.0 mg/kg and d-amphetamine at 0.5 mg/kg significantly and selectively impaired performance in the reversal phase of the task. The cognitive deficit induced by 1.5 mg/kg PCP was attenuated by prior administration of lamotrigine (20 mg/kg and 30 mg/kg) or clozapine (5 mg/kg), but not haloperidol (0.05 mg/kg). In direct contrast, haloperidol (0.05 mg/kg), but not lamotrigine (25 mg/kg) or clozapine (5 mg/kg), prevented a similar cognitive impairment produced by d-amphetamine (0.5 mg/kg). Conclusions Our findings provide further data to support the use of PCP-induced disruption of reversal learning in rodents to investigate novel antipsychotic drugs. The results also provide evidence for different mechanisms of PCP and d-amphetamine-induced disruption of performance in the test, and their different sensitivities to typical and atypical antipsychotic drugs.

The Amphetamine Years is a history of psychostimulant drugs and their clinical applications in post-World War II American medicine. Comprising such well-known substances as the amphetamines (Benzedrine, Dexedrine), methylphenidate (Ritalin), and phenmetrazine (Preludin), this class of pharmaceuticals has been among the most widely consumed in the past half-century. Their therapeutic uses for a variety of indications such as depression, obesity, and attention-deficit/hyperactivity disorder (ADHD) in children, not to mention their relevance for a number of different medical specialties, reveals that psychostimulants have occupied an important, if underappreciated role in the practice of modern medicine. In this dissertation, I illuminate the various ways in which physicians, particularly psychiatrists, put these drugs to work in clinical practice. In short, I contend that physicians exploited the wide range of physiological and psychological effects of psychostimulants and made a place for them in different therapeutic settings, even ones characterized by competing views and theories about the workings of the human body and mind. My dissertation is distinguished by two prominent themes. First, I emphasize the clinician perspective as a vehicle for understanding the history of the psychostimulants, as well as related developments in psychiatry, pharmacotherapy, and the political economy of drugs, in the second half of the twentieth century. Scholars such Nicolas Rasmussen, David Courtwright, and Ilina Singh have elucidated the history of psychostimulants by emphasizing how pharmaceutical companies positioned their products in the medical marketplace. My dissertation takes a different, yet complimentary approach by studying clinicians, themselves, to further historical comprehension of the place of these pharmaceuticals within postwar medicine, society, and culture. Second, I advance the concept of "therapeutic versatility" to explain their historical trajectories. The complex set of psychological and physical effects these drugs produced made them ideal for a diverse range of therapeutic applications, which explains why they were embraced by many different medical specialties, why they were marketed by manufacturers for a variety of indications, and why they have enjoyed an enduring therapeutic lifespan, in spite of increasing efforts since the mid-1960s to regulate their availability and control their consumption. In addition to these two overarching themes, I advance five specific arguments in my dissertation. First, I contend that pharmaceutical markets were simultaneously created by the drug industry and clinicians. Pharmaceutical firms' efforts to develop markets for their products have been well documented by historians, but in my dissertation, I underscore the role also played by clinicians in discerning drugs' applications. Second, I argue that twentieth-century psychiatry's conception of illness and therapeutics may not be served best by strictly dividing its history along lines of institutional and outpatient treatment. Third, I demonstrate how the use of psychostimulants by analytically oriented psychiatrists during the 1950s complicates historical notions of paradigm shift from a psychodynamic to biological orientation. Psychotherapy and psychopharmacology were not competing paradigms; in practice, doctors often employed both. Fourth, I assert that an appreciation of psychiatrists' empirical and eclectic approaches to the use of drugs is necessary to comprehend the rise of psychiatric pharmacotherapy in the postwar era. Finally, I contend that in order to understand the relationship between medical applications of psychostimulants and their extramedical consumption, it is necessary to conceive of a plurality of distinct "amphetamine cultures," each characterized by a unique set of relationships between physician-prescribers, patient-consumers, pharmaceutical firms, and political authorities.

Contexte: L’anhédonie, un état caractérisé par une capacité réduite d’éprouver du plaisir. Des études cliniques récentes montrent qu’un médicament antipsychotique atypique, la quétiapine, est bénéfique pour le traitement de la toxicomanie qui est supposé d’atténuer les symptômes de sevrage associés à l’usage abusif des drogues psychotropes. Le but de la présente étude était d’étudier les effets de l'administration aiguë de quétiapine sur la récompense chez des animaux en état de sevrage après un traitement chronique avec l’amphétamine. Notre hypothese est que la quetiapine va diminuer l’anhedonie causer par le sevrage. Méthodes: Les expériences ont été effectuées avec des rats mâles de la souche Sprague-Dawley entraînés à produire une réponse opérante pour obtenir une courte stimulation électrique au niveau de l'hypothalamus latéral. Des mesures du seuil de récompense ont été déterminées chez différents groupes de rats avant et pendant quatre jours après le traitement avec des doses croissantes (1 à 10 mg/kg, ip toutes les 8 heures) de d-amphétamine sulfate, ou de son véhicule, au moyen de la méthode du déplacement de la courbe. L’effet de deux doses de quétiapine a été testé 24 h après le sevrage chez des animaux traités avec l’amphétamine ou le véhicule. Résultats: Les animaux traités avec l’amphétamine ont montré une augmentation de 25% du seuil de récompense 24 h après la dernière injection, un effet qui a diminué progressivement entre le jour 1 et le jour 4, mais qui est resté significativement plus élevé en comparaison de celui du groupe contrôle. La quétiapine administrée à 2 et 10 mg/kg pendant la phase de sevrage (à 24 h) a produit une augmentation respective de 10 % et 25 % du seuil de recompense; le meme augmentation du seuil a été observe chez les animaux traitées avec le véhicule. Un augmentation de 25 % du seuil de recompense a aussi été observés chez les animaux en état de sevrage à l'amphétamine. Un test avec une faible dose d’amphétamine (1 mg/kg) avant et après le sevrage a révélé une légère tolérance à l’effet amplificateur de cette drogue sur la récompense, un phénomène qui pourrait expliquer l’effet différent de la quétiapine chez les animaux traités avec le véhicule et ceux traités avec l’amphétamine. Conclusions: Ces résultats reproduisent ceux des études précédentes montrant que la quétiapine produit une légère atténuation de la récompense. Ils montrent également que le sevrage à l’amphétamine engendre un léger état d'anhédonie et que dans cet état, une dose élevée de quetiapine et non pas une dose faible accentue l’état émotionnel négatif. Ils suggèrent qu’un traitement à faibles doses de quétiapine des symptômes de sevrage chez le toxicomane devrait ni aggraver ni améliorer son état émotionnel. / Background: Anhedonia, a condition in which the capacity of experiencing pleasure is reduced, is observed in patients that are under withdrawal from drugs of abuse. Recent clinical studies show that quetiapine may be beneficial in the treatment of substance abuse by alleviating the withdrawal-negative affect stage of addiction. This study investigated the effects of acute quetiapine on reward in animals under withdrawal from d-amphetamine. Methods: Experiments were performed on male Sprague-Dawley rats trained for intracranial self-stimulation. Measures of reward threshold were determined with the curve-shift method in different groups of rats before, and during four days after treatment with escalating doses (1 to 10 mg/kg, i.p) of d-amphetamine sulphate or its vehicle. At 24h after withdrawal, the effects of two doses of quetiapine (2 and 10 mg/kg ip) were tested in all the animals. Results: Animals treated with d-amphetamine showed 25% reward attenuation at 24h of withdrawal, an effect that decreased over the next three days. Quetiapine administered acutely at 2mg/kg and 10mg/kg on the first day of withdrawal produced 10% and 25% reward attenuation, respectively, in the vehicle-control animals, an effect also observed in the animals under withdrawal from d-amphetamine but only at the high dose. Conclusions: These results show that quetiapine produced a mild attenuation of reward in normohedonic and in anhedonic animals. They suggest that quetiapine should be used at low doses for the treatment of substance abusers under withdrawal from psychostimulant drugs to avoid enhancement of the anhedonic state.

Amphetamine (AMPH) and its derivatives embody a remarkable breadth of pharmacology. These molecules exert their effects, both therapeutic and pathological, at the human monoamine transporters, which tune synaptic dynamics by evacuating monoamine neuromodulators from the synapse subsequent to neuronal impulses. These transporters are electrogenic, and the transporter-mediated current can be correlated to a surrogate measure of the change in membrane voltage: Ca++ currents from co-transfected L-type Ca++ channels. The present work makes use of this assay, with which it is possible to derive pharmacodynamic metrics from both substrates and inhibitors. This work presents data on a heretofore-unstudied class of amphetamine analogs: the enantiomers of N-Me 4-Me AMPH and N-Et 4-Me AMPH. Remarkably, while both enantiomers of the N-Me version of this compound function as substrates at hDAT, both enantiomers of the N-Et version are inhibitors. This switch does not occur at hNET, where all enantiomers of both N-Me and N-Et 4-Me AMPH function as substrates. Further, (S)-N-Et 4-Me AMPH is a substrate at dDAT. EC50 and IC50 values for all drugs at both transporters are presented. I present the results of super-resolution microscopic co-localization studies on the plasmalemmal spatial relation of the human dopamine transporter and voltage gated calcium channel, L-type 1.2 (CaV1.2). I discuss future aims toward a unified understanding of the mechanisms of monoamine transporter function, with an emphasis on what amphetamine can illuminate in this regard.

A literatura recente sobre drogadicção trata a sensibilização produzida pela pré-exposição a estimulantes como um possível fator na aquisição, manutenção e recaída na dependência gerada por essas drogas. O objetivo desse trabalho foi verificar se a pré-exposição a dietilpropiona (DEP) e cafeína (CAF) sensibilizava ratos ao efeito reforçador da DEP. Quatro experimentos foram realizados. No Experimento 1 um grupo de ratos foi pré-exposto i.p. a DEP, enquanto outro grupo de ratos recebia veículo. Posteriormente foi medido o efeito agudo i.p. de três doses de DEP (1,0, 2,5 e 5,0 mg/kg) sobre a atividade motora. No Experimento 2, o procedimento de pré-exposição foi similar ao descrito para o Experimento 1. Posteriormente, foi medida a preferência condicionada de lugar (CPP) produzida por três doses de DEP (1,0, 2,5 e 5,0 mg/kg). O Experimento 3 constou de duas partes. Na primeira parte, ratos adultos foram pré-expostos a CAF i.p., enquanto que outro grupo recebia veículo. Posteriormente foi medida a CPP induzida por 2,5 mg/kg de DEP. Na segunda parte desse experimento, ratos adolescentes foram pré-expostos oralmente a CAF por 56 dias consecutivos, enquanto que outro grupo de ratos recebia água. Posteriormente foi medida a CPP induzida por 1,0 mg/kg de DEP. No Experimento 4, ratos adolescentes foram submetidos a um procedimento de pré-exposição similar ao descrito para a segunda parte do Experimento 3. Posteriormente foi medido o desempenho sob um esquema de razão progressiva (PR), em que os animais eram reforçados oralmente com uma solução de DEP. Os resultados do Experimento 1 mostraram que as doses de 2,5 e 5,0 mg/kg de DEP aumentaram a atividade motora. Também foi observado que, na dose de 5,0 mg/kg de DEP, esse efeito era maior para os animais que tinham sido pré-expostos, indicando que a CAF sensibilizou o efeito da DEP sobre a atividade motora. Os resultados do Experimento 2 indicaram que as doses de 2,5 e 5,0 mg/kg de DEP produziram CPP, mostrando com isso valor reforçador; porém, não foi observada sensibilização desse efeito. Os resultados do experimento 3 revelaram que nem a pré-exposição oral a CAF desde a adolescência até a idade adulta, nem a pré-exposição i.p. na idade adulta, sensibilizou o valor reforçador da DEP quando medido pelo modelo de CPP. Os resultados do Experimento 4 mostraram que a pré-exposição oral a CAF desde a adolescência até a idade adulta sensibilizou o valor reforçador da DEP quando medido pelo modelo de PR. Os resultados são discutidos em relação aos comportamento medidos pelos modelos usados para medir o valor reforçador da DEP ao potencial de dependência da DEP e à importância do consumo precoce de cafeína na vulnerabilidade à dependência de drogas. / Recent literature considers sensitization resulting from pre-exposure to psychostimulants as a possible factor in drug addiction acquisition, maintenance and relapse. The aim of this study was to verify if pre-exposure to the psychostimulants diethylpropion (DEP) and caffeine (DEP) would sensitize rats to the reinforcing value of DEP. Four experiments were conducted. In Experiment 1 a group of rats was pre-exposed to DEP while another group received vehicle. After that, the acute effect of i.p. DEP (1.0, 2.5 or 5.0 mg/kg) on motor activity was measured. A similar pre-exposure procedure was conducted in Experiment 2. After that, Conditioned Place Preference (CPP) induced by i.p. DEP (1.0, 2.5 or 5.0 mg/kg) was measured. Experiment 3 was subdivided in two parts. In the first one adult rats were pre-exposed to i.p. CAF while a control group received vehicle. After that, CPP induced by 2.5 mg/kg i.p. DEP was measured. In the second part of this experiment, adolescent rats were pre-exposed to oral CAF for 56 consecutive days, while a control group received water. After that, CPP induced by 1.0 mg/kg i.p. DEP was measured. In Experiment 4, adolescent rats were submitted to a pre-exposure procedure similar to that described for the second part of Experiment 3. After that, their responses reinforced by a DEP solution on a progressive ratio schedule (PR) were measured. Experiment 1 results showed that 2.5 and 5.0 mg/kg DEP increased motor activity. At 5.0 mg/kg this effect was more pronounced in pre-exposed animals. In Experiment 2, the doses of 2.5 and 5.0 mg/kg DEP induced CPP, demonstrating their reinforcing value. However, no sensitization effect was observed. Experiment 3 results revealed that neither pre-exposure to oral CAF from adolescence to adulthood nor i.p. CAF pre-exposure in adulthood sensitized DEP reinforcing value as measured by CPP. Experiment 4 results showed that oral CAF pre-exposure from adolescence to adulthood induced sensitization of DEP reinforcing value as measured by PR breaking point. Results are discussed in terms of the animal models to assess reinforcing value, the abuse potential of DEP and the relevance of early caffeine consumption on the vulnerability to drug dependence.

Psychological disorders such as autism, obsessive-compulsive disorder, drug addiction, and attention-deficit/hyperactivity disorder involve atypically persistent behavior and atypical activity of the neurotransmitter dopamine. Behavioral momentum theory states that the persistence of behavior in a context is determined by the reinforcement received previously in that context. Contexts previously associated with higher rates of reinforcement yield greater persistence of behavior than contexts previously associated with lower rates of reinforcement. According to a prominent hypothesis in behavioral neuroscience, dopamine mediates the incentive salience of a stimulus. A synthesis of behavioral momentum theory and the incentive salience hypothesis proposes similar roles for dopamine activity and reinforcement in determining the persistence of behavior in a context. The aim of this dissertation was to determine the extent to which a history of dopamine modulation in a context affects the subsequent persistence of behavior in extinction and relapse. Three groups of rats were trained to press a lever for food in two alternating contexts of a multiple schedule. Following a stable baseline, rats entered a treatment phase in which they received a drug or saline injection before and after sessions in each context. In the drug context, rats received the indirect dopamine agonist amphetamine, dopamine D1 antagonist SCH 23390, or a combination of amphetamine and SCH 23390 prior to the session and a saline injection following the session. The injection schedule was reversed for the saline context such that rats received a saline injection prior to each session in the saline context and a drug injection following the session. During an extinction phase, access to food was withheld. Response-independent food was then provided in each context to trigger reinstatement of responding. A history of dopamine agonism in a context increased the relative persistence of behavior, while a history of dopamine antagonism at D1 receptors and a combination of dopamine agonism and dopamine antagonism had little impact on the relative persistence of behavior. Likewise, reinstatement was relatively greater in a context previously associated with dopamine agonism. This effect was blocked when dopamine agonism was preceded by D1 antagonism. A history of D1 antagonism alone did not affect reinstatement. These results suggest that dopamine plays a role in the persistence of behavior in extinction and relapse, but that different dopamine receptors mediate these effects.